Director Rita Jain receives First Tracks (TRAXV) RSU and stock option grants

Rhea-AI Filing Summary

First Tracks Biotherapeutics, Inc. director Rita Jain reported equity awards and holdings in connection with the company’s separation from AnaptysBio. She directly holds 11,864 shares of common stock, including shares received in the spin-off distribution from AnaptysBio.

On April 20, 2026, Jain was credited with multiple stock options and restricted stock units (RSUs) that reflect adjustments under the Separation and Distribution Agreement. The filing lists stock options covering 5,500, 16,510, 16,510, 8,015, and 10,600 shares of common stock at exercise prices ranging from $3.97 to $11.75 per share, with expirations between 2033 and 2036. One option is fully vested, while another vests in twelfths monthly starting on February 6, 2026.

The RSU awards cover 4,000, 6,030, and 1,300 units, each representing the right to receive one share of common stock for no consideration. RSUs vest in tranches on June 15, 2024, June 15, 2025, and June 15, 2026, and in full on the dates of the issuer’s 2026 and 2027 annual meetings of shareholders, in each case subject to continued service.

Insider Trade Summary

9 transactions reported

Mixed 9 txns

Insider Jain Rita

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,600	$0.00	--
Grant/Award	Stock Option (right to buy)	8,015	$0.00	--
Grant/Award	Stock Option (right to buy)	16,510	$0.00	--
Grant/Award	Stock Option (right to buy)	16,510	$0.00	--
Grant/Award	Stock Option (right to buy)	5,500	$0.00	--
Grant/Award	Restricted Stock Unit	1,300	$0.00	--
Grant/Award	Restricted Stock Unit	6,030	$0.00	--
Grant/Award	Restricted Stock Unit	4,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 10,600 shares (Direct, null); Restricted Stock Unit — 1,300 shares (Direct, null); Common Stock — 11,864 shares (Direct, null)

Footnotes (1)

1. Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio"). Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. The stock option is fully vested and exercisable. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Common shares held: 11,864 shares RSU grant 1: 4,000 units RSU grant 2: 6,030 units +5 more

8 metrics

Common shares held 11,864 shares Direct holdings after transactions on April 20, 2026

RSU grant 1 4,000 units Each RSU equals 1 common share at settlement for no consideration

RSU grant 2 6,030 units Contingent right to receive common stock upon vesting

RSU grant 3 1,300 units Additional RSUs subject to service-based vesting

Option grant 5,500 shares at $11.75 Stock option fully vested and exercisable; expires January 6, 2036

Option grant 16,510 shares at $3.97 Stock option expiring January 6, 2035

Option grant 16,510 shares at $5.67 Stock option expiring January 2, 2034

Option grants 8,015 & 10,600 shares at $5.91 Two stock option positions expiring April 2, 2033

Key Terms

Restricted Stock Unit, Separation and Distribution Agreement, pro rata distribution, stock option

4 terms

Restricted Stock Unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Separation and Distribution Agreement regulatory

"...pursuant to the Separation and Distribution Agreement dated as of April 20, 2026..."

pro rata distribution financial

"Effective as of a pro rata distribution by AnaptysBio to holders of its shares..."

A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.

stock option financial

"The stock option is fully vested and exercisable."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								11,864(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.91	04/20/2026		A(2)		10,600		(3)	04/02/2033	Common Stock	10,600	$0	10,600	D
Stock Option (right to buy)	$5.91	04/20/2026		A(2)		8,015		(3)	04/02/2033	Common Stock	8,015	$0	8,015	D
Stock Option (right to buy)	$5.67	04/20/2026		A(2)		16,510		(3)	01/02/2034	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$3.97	04/20/2026		A(2)		16,510		(3)	01/06/2035	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$11.75	04/20/2026		A(2)		5,500		(4)	01/06/2036	Common Stock	5,500	$0	5,500	D
Restricted Stock Unit	(5)	04/20/2026		A(6)		1,300		(7)	(7)	Common Stock	1,300	$0	1,300	D
Restricted Stock Unit	(5)	04/20/2026		A(6)		6,030		(8)	(8)	Common Stock	6,030	$0	6,030	D
Restricted Stock Unit	(5)	04/20/2026		A(6)		4,000		(9)	(9)	Common Stock	4,000	$0	4,000	D

Explanation of Responses:

1. Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio").

2. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

3. The stock option is fully vested and exercisable.

4. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

5. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

6. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

7. The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date.

8. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

9. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Ajim Tamboli, Attorney-in-Fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Rita Jain report for First Tracks Biotherapeutics (TRAXV)?

Rita Jain reported equity awards and holdings, including stock options and restricted stock units. On April 20, 2026, she was credited with multiple option and RSU positions tied to First Tracks common stock, largely adjusted from AnaptysBio awards under a Separation and Distribution Agreement.

How many First Tracks Biotherapeutics common shares does Rita Jain hold after these transactions?

After the reported transactions, Rita Jain directly holds 11,864 shares of First Tracks common stock. This amount includes shares received in connection with the pro rata spin-off distribution from AnaptysBio to its shareholders, as described in the Form 4 footnotes.

What stock option awards did Rita Jain receive related to First Tracks Biotherapeutics (TRAXV)?

The filing lists stock options for 5,500, 16,510, 16,510, 8,015, and 10,600 First Tracks shares. Exercise prices range from $3.97 to $11.75 per share, with expiration dates from 2033 through 2036, and vesting schedules including one fully vested grant and one vesting monthly.

What are the details of the restricted stock units reported by Rita Jain at First Tracks Biotherapeutics?

Rita Jain reported RSU positions covering 4,000, 6,030, and 1,300 units. Each RSU entitles her to receive one share of First Tracks common stock for no consideration, subject to vesting based on continued service and specified dates, including June 15, 2024, 2025, and 2026.

How is the AnaptysBio spin-off connected to Rita Jain’s First Tracks equity awards?

Footnotes state that, in the pro rata distribution separating First Tracks from AnaptysBio, outstanding AnaptysBio options and RSUs were adjusted. Each became awards in both companies, so Jain acquired First Tracks options and RSUs in amounts determined under the Separation and Distribution Agreement.

When do Rita Jain’s First Tracks Biotherapeutics RSUs vest after the spin-off?

Some RSUs vest 33.33% on June 15, 2024, June 15, 2025, and June 15, 2026, subject to continued service. Additional RSU grants vest 100% on the dates of First Tracks’ 2026 and 2027 annual shareholder meetings, again contingent on Jain’s ongoing service to the issuer.